Forkhead box O1 and muscle RING finger 1 protein expression in atrophic and hypertrophic denervated mouse skeletal muscle

Ann-Kristin Fjällström*, Kim Evertsson, Marlene Norrby and Sven Tågerud

Abstract

Background: Forkhead box O (FoxO) transcription factors and E3 ubiquitin ligases such as Muscle RING finger 1 (MuRF1) are believed to participate in the regulation of skeletal muscle mass. The function of FoxO transcription factors is regulated by post-translational modifications such as phosphorylation and acetylation. In the present study FoxO1 protein expression, phosphorylation and acetylation as well as MuRF1 protein expression, were examined in atrophic and hypertrophic denervated skeletal muscle.

Methods: Protein expression, phosphorylation and acetylation were studied semi-quantitatively using Western blots. Muscles studied were 6-days denervated mouse hind-limb muscles (anterior tibial as well as pooled gastrocnemius and soleus muscles, all atrophic), 6-days denervated mouse hemidiaphragm muscles (hypertrophic) and innervated control muscles. Total muscle homogenates were used as well as separated nuclear and cytosolic fractions of innervated and 6-days denervated anterior tibial and hemidiaphragm muscles.

Results: Expression of FoxO1 and MuRF1 proteins increased 0.3-3.7-fold in all 6-days denervated muscles studied, atrophic as well as hypertrophic. Phosphorylation of FoxO1 at S256 increased about 0.8-1-fold after denervation in pooled gastrocnemius and soleus muscles and in hemidiaphragm but not in unfractonated anterior tibial muscle. A small (0.2-fold) but statistically significant increase in FoxO1 phosphorylation was, however, observed in cytosolic fractions of denervated anterior tibial muscle. A statistically significant increase in FoxO1 acetylation (0.8-fold) was observed only in denervated anterior tibial muscle. Increases in total FoxO1 and in phosphorylated FoxO1 were only seen in cytosolic fractions of denervated atrophic anterior tibial muscle whereas in denervated hypertrophic hemidiaphragm both total FoxO1 and phosphorylated FoxO1 increased in cytosolic as well as in nuclear fractions. MuRF1 protein expression increased in cytosolic as well as in nuclear fractions of both denervated atrophic anterior tibial muscle and denervated hypertrophic hemidiaphragm muscle.

Conclusions: Increased expression of FoxO1 and MuRF1 in denervated muscles (atrophic as well as hypertrophic) suggests that these proteins participate in the tissue remodelling occurring after denervation. The effect of denervation on the level of phosphorylated and acetylated FoxO1 differed in the muscles studied and may be related to differences in fiber type composition of the muscles.

Keywords: Acetylation, Atrophy, Denervation, Cytosolic fraction, Forkhead box O, Hypertrophy, MuRF1, Nuclear fraction, Phosphorylation, Skeletal muscle

* Correspondence: ann-kristin.fjallstrom@lnu.se
Department of Chemistry and Biomedical Sciences, Linnaeus University,
Kalmar SE-391 82, Sweden

© 2014 Fjällström et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Skeletal muscle normally makes up about 45% of the body mass in humans [1] but is a very plastic tissue responsive to alterations in usage. Muscle inactivity leads to a decrease in mass (atrophy) whereas increased activity leads to an increase in mass (hypertrophy). Such changes in muscle mass are believed to occur as a result of alterations in a delicate balance between pathways regulating muscle protein synthesis and degradation [2]. The Forkhead box O (FoxO) transcription factors FoxO1 and FoxO3 are believed to participate in the regulation of muscle mass since overexpression of these transcription factors has been shown to lead to reduced skeletal muscle mass [3,4].

FoxO transcription factors include the four members FoxO1 (FKHR), FoxO3 (FKHRL1), FoxO4 (AFX) and FoxO6 [5-7]. These are reported to have important roles in e.g. stress resistance and metabolism by regulating the expression of target genes. Examples of environmental stimuli that get translated by FoxO transcription factors into specific gene expression programs include oxidative stress, nutrients and growth factors [8]. In growing cells FoxO proteins are to a high extent located in the cytoplasm [9] since nuclear export is a response to growth signals and nuclear import is a response to stress signals such as oxidative stress [9,10].

One effect of FoxO transcription factors that may be important for the regulation of muscle mass is related to the control of transcription of E3 ubiquitin ligases such as Muscle RING finger 1 (MuRF1) and muscle atrophy F-box (MAFbx, Atrogin1). The mRNA expression of these ubiquitin ligases increase in a number of different atrophic conditions, including immobilization, hind-limb suspension, starvation, glucocorticoid treatment and denervation [11-17]. Similarly the mRNA expression of FoxO1 has been shown to increase in a number of atrophic conditions including denervation [12,15,18]. Constitutively active FoxO1, however, did not increase the expression of MAFbx or MuRF1 in myotubes [19] and transgenic mice overexpressing FoxO1 do not have consistent alterations in MAFbx or MuRF1 levels [4]. FoxO1 has, however, been found to cooperate with the glucocorticoid receptor to synergistically activate transcription of a reporter gene driven by the MuRF1 promoter [20]. The nuclear content of FoxO1 protein has been shown to decrease in human quadriceps muscle after resistance training, associated with muscle growth, and then during a de-training period the amount of FoxO1 protein increased in the nucleus [21].

The functions of FoxO transcription factors are controlled by post-translational modifications such as phosphorylation, acetylation and ubiquitination that influence transport between the nucleus and cytoplasm [22]. FoxO transcription factors can be phosphorylated by a number of different kinases including Akt (protein kinase B). FoxO1 is phosphorylated by Akt on S253, S316 and T24 (mouse FoxO1 sequence). The phosphorylations occur sequentially starting with S253 in the forkhead domain [9]. Following phosphorylation FoxO transcription factors bind to 14-3-3 chaperone proteins and are transported out of the nucleus to the cytoplasm. The 14-3-3 binding masks the nuclear localization signal and this prevents FoxO from returning to the nucleus [10]. In C2C12 myotubes glucocorticoid treatment or removal of growth medium has been shown to decrease the phosphorylation of FoxO1 [3]. FoxO1 can also be acetylated at a number of different sites and acetylation seems to have an inhibitory effect on DNA binding capability but may also stimulate phosphorylation on S253 indicating that acetylation and phosphorylation may work together to control the function of FoxO1 [7,23].

The purpose of the present study was to investigate FoxO1 protein expression, phosphorylation and acetylation as well as MuRF1 protein expression in atrophic (hind-limb) and hypertrophic (hemidiaphragm) 6-days denervated mouse skeletal muscle. The hemidiaphragm muscle becomes transiently hypertrophic for 6–10 days following denervation [24-26] whereas hind-limb muscles atrophy continuously following denervation. The hemidiaphragm of the mouse contains mainly type II muscle fibers with a lower content (about 12%) of type I fibers [27]. The hind-limb muscles used in the present study were anterior tibial muscles that in the mouse are devoid of type I muscle fibers [28] and pooled gastrocnemius and soleus muscles that in addition to type II also contain type I muscle fibers [28,29].

Results

All results reported are based on data from 7 sets of 8 animals generating 16 denervated anterior tibial muscles with 16 contralateral innervated controls (8 innervated and 8 denervated muscles used for whole muscle protein extraction and 8 innervated and 8 denervated muscles used for preparing separate cytosolic and nuclear fractions), 8 denervated pooled gastrocnemius and soleus muscles with 8 contralateral innervated controls (all used for whole muscle protein extraction), 16 denervated hemidiaphragm muscles, 16 innervated control hemidiaphragms from separate animals (8 innervated and 8 denervated muscles used for whole muscle protein extraction and 8 innervated and 8 denervated muscles used for preparing separate cytosolic and nuclear fractions) and 8 hemidiaphragm muscles from sham operated animals (all used for whole muscle protein extraction).

Muscle weights

Alterations in muscle weights following 6 days of denervation are illustrated in Figure 1 for muscles used for
whole muscle protein extraction. Six days after denervation hemidiaphragm muscles were hypertrophic with a wet weight of $43.3 \pm 0.7$ mg ($n = 8$, $p < 0.001$ versus innervated and sham operated, one-way ANOVA with Tukey’s multiple comparisons test, Figure 1) compared to innervated controls with a wet weight of $28.2 \pm 0.8$ mg ($n = 8$) and sham operated control muscles with a wet weight of $29.7 \pm 1.0$ mg ($n = 8$). After six days of denervation anterior tibial muscles were atrophic with a wet weight of $51.6 \pm 1.8$ mg ($n = 8$), compared to innervated controls with a wet weight of $65.9 \pm 1.8$ mg ($n = 8$, $p < 0.001$, Student’s paired t-test, Figure 1). After six days of denervation pooled gastrocnemius and soleus muscles were atrophic with a wet weight of $149.1 \pm 4.4$ mg ($n = 8$), compared to innervated controls with a wet weight of $198.3 \pm 5.7$ mg ($n = 8$, $p < 0.001$, Student’s paired t-test, Figure 1).

Weights of muscles used for preparing separated nuclear and cytosolic fractions were as follows. 6-days denervated hemidiaphragm muscles were hypertrophic with a wet weight of $40.3 \pm 1.5$ mg ($n = 8$) compared to innervated controls with a wet weight of $29.6 \pm 0.6$ mg ($n = 8$, $p < 0.001$, Student’s t-test). 6-days denervated anterior tibial muscles were atrophic with a wet weight of $44.7 \pm 1.8$ mg ($n = 8$), compared to innervated controls with a wet weight of $60.8 \pm 1.9$ mg ($n = 8$, $p < 0.001$, Student’s paired t-test).

**FoxO1 expression in 6-days denervated atrophic and hypertrophic muscle**

FoxO1 protein expression increased 0.8-3.7-fold in all 6-days denervated muscles studied, atrophic as well as hypertrophic (Figure 2).

The mean expression level of total FoxO1 protein in anterior tibial muscles was $383.8 \pm 131.0$ arbitrary units ($n = 8$) in denervated muscles compared to $100.0 \pm 31.1$ (n = 8) in innervated muscles ($p < 0.05$, Student’s paired t-test, Figure 2A). The mean protein expression level in pooled gastrocnemius and soleus muscles was $179.5 \pm 10.7$ arbitrary units ($n = 8$) in denervated muscles compared to $100.0 \pm 11.9$ (n = 8) in innervated muscles ($p < 0.01$, Student’s paired t-test, Figure 2B). The mean protein expression level in hemidiaphragm muscles was $471.0 \pm 173.1$ arbitrary units in denervated muscles ($n = 8$, $p < 0.05$ versus innervated and sham operated, Kruskal-Wallis test with Dunn’s multiple comparisons test, Figure 2C) compared to $100.0 \pm 59.5$ (n = 8) in innervated muscles and $70.7 \pm 33.6$ (n = 8) in sham operated control muscles (Figure 2C).

**FoxO1 phosphorylation in 6-days denervated atrophic and hypertrophic muscle**

Levels of phosphorylated FoxO1 were unchanged in 6-days denervated anterior tibial muscle (atrophic) but increased about 0.8-1-fold in 6-days denervated hemidiaphragm (hypertrophic) and in pooled 6-days denervated gastrocnemius and soleus muscles (atrophic, Figure 3).

The mean expression level of phosphorylated FoxO1 in anterior tibial muscles was $93.3 \pm 21.9$ arbitrary units ($n = 8$) in denervated muscles compared to $100.0 \pm 28.6$ (n = 8) in innervated muscles (Figure 3A). The mean expression level in pooled gastrocnemius and soleus muscles was $196.1 \pm 24.6$ arbitrary units ($n = 8$) in denervated muscles compared to $100.0 \pm 13.1$ (n = 8) in innervated muscles ($p < 0.01$, Student’s paired t-test, Figure 3B). The mean expression level in hemidiaphragm muscles was $178.5 \pm 27.9$ arbitrary units in denervated muscles ($n = 8$, $p < 0.05$ versus innervated and $p < 0.01$ versus sham operated, one-way ANOVA with Tukey’s multiple comparisons test, Figure 3C) compared to $100.0 \pm 12.6$ (n = 8) in innervated muscles and $74.0 \pm 12.7$ (n = 8) in sham operated control muscles (Figure 3C).

**FoxO1 acetylation in 6-days denervated atrophic and hypertrophic muscle**

The level of acetylated FoxO1 increased about 0.8-fold in 6-days denervated anterior tibial muscles (atrophic) but no statistically significant changes were seen in 6-days denervated pooled gastrocnemius and soleus muscles (atrophic) nor in 6-days denervated hemidiaphragm muscles (hypertrophic, Figure 4).

The mean expression level of acetylated FoxO1 in anterior tibial muscles was $183.5 \pm 36.2$ arbitrary units ($n = 8$) in denervated muscles compared to $100.0 \pm 16.7$ (n = 8) in innervated muscles ($p < 0.01$, Wilcoxon matched-pairs signed rank test, Figure 4A). The mean expression level of acetylated FoxO1 in pooled gastrocnemius and soleus muscles was $114.6 \pm 10.6$ arbitrary units ($n = 8$) in denervated muscles compared to $100.0 \pm 11.6$ (n = 8) in innervated muscles (Figure 4B). The mean expression level of acetylated FoxO1 in hemidiaphragm muscles was...
99.8 ± 10.3 arbitrary units (n = 8) in denervated muscles compared to 100.0 ± 19.8 (n = 8) in innervated muscles and 109.5 ± 15.8 (n = 8) in sham operated control muscles (Figure 4C).

MuRF1 expression in in 6-days denervated atrophic and hypertrophic muscle

MuRF1 protein expression increased 0.3-0.9-fold in all 6-days denervated muscles studied, atrophic as well as hypertrophic (Figure 5).

The mean expression level of MuRF1 protein in anterior tibial muscles was 132.6 ± 21.2 arbitrary units (n = 8) in denervated muscles compared to 100.0 ± 17.2 (n = 8) in innervated muscles (p < 0.01, Wilcoxon matched-pairs signed rank test, Figure 5A). The mean protein expression level in pooled gastrocnemius and soleus muscles was 189.0 ± 15.6 arbitrary units (n = 7) in denervated muscles compared to 100.0 ± 13.0 (n = 7) in innervated muscles (p < 0.05, Wilcoxon matched-pairs signed rank test, Figure 5B). The mean protein expression level in hemidiaphragm muscles was 170.9 ± 10.4 arbitrary units in denervated muscles (n = 8, p < 0.05 versus innervated muscles, one-way ANOVA with Tukey’s multiple comparisons test, Figure 5C) compared to 100.0 ± 13.3 (n = 8) in innervated muscles and 111.3 ± 24.3 in sham operated control muscles (Figure 5C).

FoxO1 protein expression and phosphorylation in cytosolic and nuclear fractions of 6-days denervated atrophic anterior tibial muscle

In innervated as well as in 6-days denervated atrophic anterior tibial muscle total and phosphorylated FoxO1 protein were mainly present in cytosolic fractions. Expression increased about 1-fold and 0.2-fold, respectively, in cytoplasmic fractions of 6-days denervated muscles (Figure 6).

The mean expression level of total FoxO1 protein in the cytosolic fraction of anterior tibial muscles was 136.7 ± 14.7 arbitrary units (n = 8) in denervated muscles compared to 66.9 ± 4.4 (n = 8) in innervated muscles (p < 0.01, Student’s paired t-test). In the nuclear fraction
the expression level of total FoxO1 protein in denervated muscle was 23.7 ± 4.2 arbitrary units (n = 8) compared to 33.1 ± 5.0 (n = 8) in innervated muscles (Figure 6A).

The mean expression level of phosphorylated FoxO1 in the cytosolic fraction of anterior tibial muscles was 97.9 ± 5.6 arbitrary units (n = 8) in denervated muscles compared to 84.8 ± 5.1 (n = 8) in innervated muscles (p < 0.01, Student’s paired t-test). In the nuclear fraction the expression level of phosphorylated FoxO1 in denervated muscle was 16.7 ± 3.4 arbitrary units (n = 8) compared to 15.2 ± 4.9 (n = 8) in innervated muscles (Figure 6B).

**Figure 3** FoxO1 phosphorylation in 6-days denervated atrophic hind-limb muscles and in 6-days denervated hypertrophic hemidiaphragm muscle. Expression of phosphorylated FoxO1 in 6-days denervated (Den) atrophic anterior tibial muscle (A), atrophic pooled gastrocnemius and soleus muscles (B), and in hypertrophic hemidiaphragm muscle (C) compared to innervated (Inn) and sham operated controls. Representative images of Western blots are shown together with densitometric quantifications. One innervated sample from the respective muscle type was loaded onto all gels as a reference. All samples were measured relative to this reference. The data were normalized to give a mean value of 100.0 in innervated muscles. Mean values ± standard error of the mean. *p < 0.05, **p < 0.01, n = 8 muscles per group.

FoxO1 protein expression and phosphorylation in cytosolic and nuclear fractions of 6-days denervated hypertrophic hemidiaphragm muscle

In innervated as well as in 6-days denervated hypertrophic hemidiaphragm muscle total and phosphorylated FoxO1 protein were mainly present in cytosolic fractions. Expression of total FoxO1 protein increased about 1.7-fold and 1.4-fold, respectively, in cytoplasmic and nuclear fractions of 6-days denervated muscles. Expression of phosphorylated FoxO1 increased about 1.3-fold and 2.5-fold, respectively, in cytoplasmic and nuclear fractions of 6-days denervated muscles (Figure 7).

The mean expression level of total FoxO1 protein in the cytosolic fraction of hemidiaphragm muscles was 204.8 ± 32.2 arbitrary units (n = 8) in denervated muscles compared to 77.2 ± 16.6 (n = 8) in innervated muscles (p < 0.01, Student’s t-test). In the nuclear fraction the expression level of total FoxO1 protein in denervated muscle was 54.8 ± 10.1 arbitrary units (n = 8) compared to 22.8 ± 5.5 in innervated muscles (p < 0.05, Student’s t-test, Figure 7A).

The mean expression level of phosphorylated FoxO1 in the cytosolic fraction of hemidiaphragm muscles was 213.3 ± 41.8 arbitrary units (n = 8) in denervated muscles compared to 92.8 ± 25.3 (n = 8) in innervated muscles (p < 0.05, Mann–Whitney test). In the nuclear fraction the expression level of phosphorylated FoxO1 in denervated muscle was 25.2 ± 4.8 arbitrary units (n = 8) compared to 7.2 ± 2.0 in innervated muscles (p < 0.01, Student’s t-test, Figure 7B).
MuRF1 expression in cytosolic and nuclear fractions of 6-days denervated atrophic and hypertrophic muscle

In innervated as well as in 6-days denervated atrophic anterior tibial muscle and hypertrophic hemidiaphragm muscle MuRF1 protein was mainly present in cytosolic fractions. Expression increased about 0.5-2.4-fold in cytoplasmic as well as nuclear fractions of 6-days denervated muscles (Figure 8).

The mean expression level of MuRF1 protein in the cytosolic fraction of anterior tibial muscles was 90.2 ± 12.2 arbitrary units (n = 8) in denervated muscles compared to 60.4 ± 10.2 (n = 8) in innervated muscles (p < 0.05, Student’s paired t-test). In the nuclear fraction the expression level of MuRF1 protein in denervated muscle was 62.0 ± 10.2 arbitrary units (n = 8) compared to 39.6 ± 6.1 (n = 8) in innervated muscles (p < 0.05, Student’s paired t-test, Figure 8A).

The mean expression level of MuRF1 protein in the cytosolic fraction of hemidiaphragm muscles was 134.5 ± 21.6 arbitrary units (n = 8) in denervated muscles compared to 80.5 ± 9.3 (n = 8) in innervated muscles (p < 0.05, Student’s t-test). In the nuclear fraction the expression level of MuRF1 protein in denervated muscle was 67.1 ± 10.4 arbitrary units (n = 8) compared to 19.5 ± 2.1 in innervated muscles (p < 0.001, Student’s t-test, Figure 8B).

Discussion

The present study has examined the expression of FoxO1 protein and post-translational modifications of FoxO1 in models of atrophic and hypertrophic denervated skeletal muscle. Most denervated skeletal muscles atrophy but the hemidiaphragm muscle undergoes a transient hypertrophy following denervation possibly as a result of passive stretching due to continued contractions in the contralateral innervated hemidiaphragm [24-26]. The hemidiaphragm of the mouse is composed mainly of type II muscle fibers but also contains about 12% of type I fibers [27]. The hind-limb muscles used in the present study were mouse anterior tibial muscles that are devoid of type I muscle fibers [28] and pooled gastrocnemius and soleus...
muscles that in addition to type II also contain type I muscle fibers [28,29].

Similar to what has previously been shown for FoxO3 [30-32], and recently also for FoxO1 in atrophic hind-limb muscle [33], the present study shows that the expression of FoxO1 protein is increased in 6-days denervated skeletal muscle. This increase was observed in all denervated muscles studied, atrophic as well as hypertrophic, suggesting that FoxO1 plays a role for denervation changes other than those leading to alterations in muscle mass. One such role may relate to the expression of different myosin heavy chain isoforms. Thus, overexpression of FoxO1 has previously been shown to result in a decrease in type I muscle fibers and a strong reduction in the expression of the slow muscle myosin heavy chain isoform [4]. Similarly, in soleus and gastrocnemius muscles denervation has been shown to reduce the expression of the slow muscle myosin heavy chain isoform [34,35]. Increased FoxO1 expression has also been reported in hypertrophic mouse plantaris muscle following functional overload [36,37].

Phosphorylation of FoxO1 at S256 increased in pooled gastrocnemius and soleus muscles (atrophic with type I fibers) as well as in hemidiaphragm (hypertrophic with type I fibers) but not in unfractionated anterior tibial muscle (atrophic without type I fibers). A small but statistically significant increase in FoxO1 phosphorylation was, however, observed in the cytosolic fraction of denervated anterior tibial muscle. The difference in phosphorylated FoxO1 between denervated anterior tibial and pooled gastrocnemius and soleus muscles might be related to FoxO1 being more readily phosphorylated in type I muscle fibers as suggested by a higher p-FoxO1/FoxO1 ratio in soleus muscle compared to anterior tibial muscle [31]. A statistically significant increase in FoxO1 acetylation was observed only in denervated anterior tibial muscle. A previous study has reported increased acetylation of FoxO3 in denervated anterior tibial muscle but at later times following denervation [30].

FoxO1 protein expression and phosphorylation were also studied in separated cytosolic and nuclear fractions

Figure 5 MuRF1 protein expression in 6-days denervated atrophic hind-limb muscles and in 6-days denervated hypertrophic hemidiaphragm muscle. MuRF1 expression in 6-days denervated (Den) atrophic anterior tibial (A), atrophic pooled gastrocnemius and soleus muscles (B) and in hypertrophic hemidiaphragm muscle (C) compared to innervated (Inn) and sham operated controls. Representative images of Western blots are shown together with densitometric quantifications. One innervated sample from the respective muscle type was loaded onto all gels as a reference. All samples were measured relative to this reference. The data were normalized to give a mean value of 100.0 in innervated muscles. Mean values ± standard error of the mean. *p < 0.05, **p < 0.01, n = 8 (A and C) or 7 (B) muscles per group.
of hemidiaphragm and anterior tibial muscles. In all muscles studied, innervated as well as denervated atrophic and denervated hypertrophic muscles, total and phosphorylated FoxO1 protein were mainly present in cytosolic fractions. In anterior tibial muscle increases in protein expression and phosphorylation were only observed in cytosolic fractions following denervation. In hemidiaphragm total FoxO1 protein, as well as phosphorylated protein, were increased in nuclear as well as in cytosolic fractions following denervation. A previous study has also reported increased nuclear FoxO1 in denervated rat hemidiaphragm although only at early times (1 day) after denervation, but not after 5 days [38].

MuRF1 protein expression has previously been reported to increase in denervated hind-limb muscle [33,39,40]. The present study confirms increased MuRF1 protein

**p < 0.01, n = 8 denervated anterior tibial muscles and 8 contralateral innervated control muscles.**

**p < 0.05, **p < 0.01, n = 8 denervated hemidiaphragms and 8 innervated control hemidiaphragms from separate animals. Each muscle was fractionated into a cytosolic and a nuclear fraction.
expression in denervated atrophic hind-limb muscle but also shows that MuRF1 protein expression is increased in denervated hemidiaphragm muscle at a time point when the muscle is in a hypertrophic state relative to innervated control muscles. Despite the hypertrophic state previous studies on denervated rat hemidiaphragm indicate that from 5 days following denervation protein degradation, as well as protein synthesis, is increased in this muscle [41].

Expression of MuRF1 has been reported to be controlled by myogenin and deletion of myogenin diminishes the expression of MuRF1 in denervated hind-limb muscles [42,43]. Increased expression of MuRF1 in denervated muscle may therefore be a consequence of the increased expression of myogenin that occurs following denervation in hind-limb as well as in hemidiaphragm muscle [44-46]. MuRF1 has also been shown to be preferentially expressed in type II muscle fibers, and also to be preferentially induced in type II fibers after denervation [40,47]. All muscles included in the present study contain type II muscle fibers but the fiber type composition of muscles changes following denervation [48,49]. It is, thus, also possible that the increased MuRF1 expression observed in the present study relates to alterations in fiber types that occur following denervation.

Conclusions

Increased expression of FoxO1 and MuRF1 in denervated muscles (atrophic as well as hypertrophic) suggests that these proteins participate in the tissue remodelling that occurs in skeletal muscle following denervation. The effect of denervation on the level of phosphorylated and acetylated FoxO1 differed in the muscles studied and may be related to differences in fiber type composition of the muscles.

Methods

Animals and muscles

Adult male NMRI mice (Scanbur, Sollentuna, Sweden) were used in this study. The mice were kept in cages with environment enrichment and with free access to a standard laboratory diet and tap water. The animals were anaesthetized by inhalation of isoflurane before surgery and received a subcutaneous injection of buprenorphine (50 μg/kg) for post-operative analgesia. Denervation of either the left hemidiaphragm or the left hind-limb was performed by sectioning and removing a few mm of the phrenic nerve or the sciatic nerve as described previously [50]. Six days after denervation the mice were killed by cervical dislocation. Hind-limb muscles (anterior tibial and gastrocnemius together with soleus) were rapidly dissected, weighed, frozen on dry ice and stored at −80°C. Innervated control hind-limb muscles were collected from the contralateral (right) leg of animals that were denervated by sectioning the left sciatic nerve. Innervated left control hemidiaphragms were collected from separate animals that had received no surgery. To control for this, eight animals used for hemidiaphragm studies went through sham surgery. These animals were anaesthetized by inhalation of isoflurane, had a subcutaneous injection of buprenorphine (50 μg/kg) and a unilateral thoracotomy without touching the phrenic nerve. For dissection of the hemidiaphragm muscle the diaphragm, attached to the rib
cage, was quickly removed and placed in cold phosphate buffered saline (PBS) with calcium (2 mM). The left hemidiaphragm was then dissected under a dissecting microscope, blotted dry on filter paper, weighed, frozen on dry ice and stored at −80°C. The experimental manipulations have been approved by the Ethical Committee for Animal Experiments, Linköping, Sweden (permit number: 67–10).

Protein extraction
Hemidiaphragm, anterior tibial and pooled gastrocnemius and soleus muscles were used for protein extractions. The muscles were homogenized using an Ultra-Turrax homogenizer (Janke and Kunkel, Staufen, Germany) in 1 ml (hemidiaphragm and anterior tibial muscles) or 2 ml (pooled gastrocnemius and soleus muscles) buffer containing 100 mM Tris–HCl, pH 7.6, 150 mM NaCl, 1 mM EDTA, 0.1% sodium deoxycholate and 1% Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, Rockford, IL). The supernatant was recovered and the pellet was resuspended in 0.5 ml (anterior tibial and hemidiaphragm muscles) or 1.0 ml (pooled gastrocnemius and soleus muscles) of homogenization buffer and recentrifuged. The supernatants were combined and the protein concentration was determined using the Bradford assay [51].

Cytosolic and nuclear skeletal muscle fractions
Mouse hemidiaphragm and anterior tibial muscles were used for cytosolic and nuclear protein extraction. The method used was slightly modified from [52] and has been described separately [53]. In brief, muscles that had been stored at −80°C were homogenized using an Ultra-Turrax homogenizer (Janke and Kunkel, Staufen, Germany) in 1 ml low salt lysis buffer (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl₂, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol (DTT); pH 7.9 with 1% Halt™ Protease and Phosphatase Inhibitor Cocktail from Thermo Scientific, Rockford, IL). The homogenized tissue was then vortexed (15 s), put on ice (10 min), vortexed again (15 s) and centrifuged (16,000 g for 15 s). The supernatant cytosolic extract was frozen at −80°C for subsequent analyses. The nuclear pellet was resuspended on ice in a high salt nuclear extraction buffer (20 mM HEPES, 420 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 25% glycerol; pH 7.9 with 1% Halt™ Protease and Phosphatase Inhibitor Cocktail from Thermo Scientific, Rockford, IL). Four μl of nuclear extraction buffer was used per mg muscle wet weight. Preparations were incubated on ice for 30 min and vortexed (10 s) every 5 min before centrifugation (16,000 g for 6 min). The supernatant nuclear extract was frozen at −80°C for subsequent analyses. Protein determinations for each fraction were obtained using the Bradford assay [51].

Western blot
Western blots were prepared essentially as described in [50]. Fifteen to thirty μg protein were reduced, denatured and electrophoretically separated on a 12% polyacrylamide gel with a 5.2% polyacrylamide stacking gel on top. Gels were electroblotted onto PVDF Plus transfer membranes (Amersham Hybond-P, GE Healthcare, Buckinghamshire, England) and the membranes were blocked and then incubated with antibodies. Primary antibodies for detecting total-FoxO1 (rabbit monoclonal) (C29H4) [2880] and pFoxO1 S256 (rabbit polyclonal) [9461] were obtained from Cell Signaling Technology (Beverly, CA), MuRF1 (goat polyclonal) [AF5366] was obtained from R&D systems (Abingdon, England) and Ac-FoxO1 (rabbit polyclonal) (FKHR D19) [49437] from Santa Cruz Biotecnology (Santa Cruz, CA). All primary antibodies were used at a dilution of 1/800 – 1/1500. Antibodies were visualized with horseradish peroxidase conjugated secondary immunoglobulin diluted 1/1000 goat anti-rabbit IgG [P0448] and 1/1000-1/10000 rabbit anti-goat IgG [P0449] (Dako, Glostrup, Denmark). The bound immune complexes were detected using the ECL Plus Western blotting detection system and Hyperfilm ECL (Amersham International and Amersham Pharmacia Biotech, Buckinghamshire, England).

Data analysis and statistics
The expression levels of total, phosphorylated and acetylated proteins were studied semi-quantitatively using data from Western blots. Equal amounts of total, cytosolic or nuclear proteins from innervated or denervated muscles were loaded on the gels. Measured levels of total, phosphorylated or acetylated proteins are expressed without normalization to any specific protein. No loading controls were used and any difference in protein quantifications, pipetting steps, protein transfers etc. are included in the variations of the data sets.

Image analysis was performed using the gel plotting macro of the program ImageJ (Rasband, W.S., ImageJ, US National Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij/, 1997–2007). Results were obtained in uncalibrated optical density units

In order to be able to compare data for whole muscle homogenates run on different gels, one innervated muscle sample (a reference sample) was included in all gels containing samples to be compared to each other. All other samples were measured relative to this reference, the signal of which was set to 100.0 in all gels. In order to more easily compare denervated and innervated muscles all data were finally normalized in such a way that the average signal from innervated muscles became 100.0.

For quantification of protein expression in separated cytosolic and nuclear fractions one of the cytosolic fractions from an innervated muscle was used as a reference.
sample and was included in all gels. All other samples were measured relative to this reference, the signal of which was set to 100.0. From the amount of protein loaded on gels in relation to the total amount of protein extracted in the nuclear and cytosolic fractions a total cytosolic and a total nuclear signal was calculated for whole muscles. In the final analysis total cytosolic and total nuclear signals were again normalized in such way that the sum of the nuclear and cytosolic signals became 100.0 in innervated muscle.

Data are presented as mean values ± standard error of the mean (SEM). For statistical comparisons of unfractinated hemidiaphragm muscles (innervated, sham operated and denervated) one way-ANOVA was used, followed by Tukey’s multiple comparisons test, for normally distributed data (according to D’Agostino-Pearson omnibus K2 normality test). Statistical significance for data not being normally distributed was determined using the Kruskal-Wallis test with Dunn’s multiple comparisons test. For other comparisons Student’s t-test (paired observations for hind-limb muscles, unpaired observations for hemidiaphragm muscles) was used for normally distributed data. Statistical significance for data not being normally distributed was determined using the Wilcoxon matched-pairs signed rank test (hind-limb muscles) or the Mann-Whitney test (hemidiaphragm muscles).

Competing Interests
The authors declare that they have no competing interests.

Authors’ contributions
The work presented here was carried out in collaboration between all authors. AKF designed the study and carried out most of the protein expression studies, statistical analyses and drafted the manuscript. KE carried contributions and statistical analyses and drafted the manuscript. All authors have read and approved the final manuscript.

Acknowledgements
We would like to thank Amanda Nyström for help with the MuRF1 studies. This work was supported by grants from the Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden.

Received: 3 April 2014 Accepted: 18 September 2014
Published: 24 September 2014

References
1. Spargo E, Pratt OE, Daniel PM: Metabolic functions of skeletal muscles of man, mammals, birds and fishes: a review. J R Soc Med 1979, 72:921–925.
2. Schiaffino S, Dyar KA, Ciciorat S, Blauw R, Sandri M: Mechanisms regulating skeletal muscle growth and atrophy. FEBS J 2013, 280:4294–4314.
3. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Leverk SH, Goldberg AL: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399–412.
4. Kemel Y, Miura S, Suzuki K, Kinugasa Y, Mizukami O, Taniguchi T, Mochida K, Hata T, Matsuura H, Aburatani H, Nishino I, Ezaki O: Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 2004, 279:41114–41123.
5. Olsbo T, Olsbova V: Structure/function relationships underlying regulation of FOXO transcription factors. Oncogene 2008, 27:2263–2275.
6. Zhao Y, Wang Y, Zhu WG: Applications of post-translational modifications of FOXO family proteins in biological functions. J Mol Cell Biol 2011, 3:276–282.
7. Daitoku H, Sakamaki J, Fukunishima K: Regulation of FOXO transcription factors by acetylation and protein-protein interactions. Biochim Biophys Acta 1813, 2011:1954–1960.
8. Calnan DR, Brunet A: The FoxO code. Oncogene 2008, 27:2276–2288.
9. Vogt PK, Jiang H, Acki M: Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 2005, 4:508–913.
10. Huang H, Tindall DJ: Dynamic FOXO transcription factors. J Cell Sci 2012, 120:2479–2487.
11. Bodine SC, Latres E, Baumhueter S, Lai WM, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na EQ, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Sitt DN, Yancopoulos GD, Glass DJ: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294:1704–1708.
12. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004, 18:39–51.
13. Sachock MM, Ohtsuka A, McSavry CL, Goldberg AL: IGFl-stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol-Endocrinol Metabol 2004, 287:E591–E601.
14. Latres E, Arini AR, Amini AA, Griffiths J, Martin FJ, Wei Y, Lin HC, Yancopoulos GD, Glass DJ: Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 2005, 280:2757–2764.
15. Sachack MJ, Hyatt JPK, Raffaello A, Jagoe RT, Roy RR, Edgerton VR, Lecker SH, Goldberg AL: Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. Faseb J 2007, 21:140–155.
16. Foletta VC, White LI, Larsen AE, Leger B, Russell AP: The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy. Pflug Arch 2011, 463:335–355.
17. Llan-de-Piez M, Gustafson AM, Olsson C, Goransson H, Larsson I: Muscle wasting and the temporal gene expression pattern in a novel rat intensive care unit model. BMC Genomics 2011, 12:602.
18. Furuyama T, Kitayama K, Yamashita H, Mori N: Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation. Biochem J 2003, 375:365–371.
19. Sitt TN, Dujan D, Clarke BA, Panaro F, Timofeyeva Y, Kline WC, Gonzalez M, Yancopoulos GD, Glass DJ: The IGF-I/PI3K/Akt pathway prevents short article expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004, 14:395–403.
20. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, Furlow JD, Bodine SC: The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol-Endocrinol Metabol 2008, 295:E835–E847.
21. Leger B, Cartoni R, Praz M, Lamon S, Derier O, Cretanend A, Gobelet C, Rohmer P, Konzelmann M, Luth F, Russell AP: Akt signalling through GSK-3 beta, mTOR and FOXO1 is involved in human skeletal muscle hypertrophy and atrophy. J Physiol-London 2006, 576:923–934.
22. Tzivion G, Dobson M, Ramakrishnan G: FOXO transcription factors: regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 2011, 1813:2011:1938–1945.
23. Matsuzaki H, Daitoku H, Hatta M, Aoyama H, Yoshimochi K, Fukamizu A: Regulation of FoxO transcription factors by AKT and 14-3-3 proteins. Biochim Biophys Acta 2011, 1813:2011:1938–1945.
24. Tzivion G, Dobson M, Ramakrishnan G: FOXO transcription factors: regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 2011, 1813:2011:1938–1945.
25. Matsuzaki H, Daitoku H, Hatta M, Aoyama H, Yoshimochi K, Fukamizu A: Acetylation of FOXO1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc Natl Acad Sci U S A 2005, 102:11278–11283.
26. Calnan DR, Martin AW: Denervation hypertrophy and atrophy of the hemidiaphragm of the rat. Am J Physiol 1953, 172:234–232.
27. Feng TP, Lu DX: New lights on the phenomenon of transient hypertrophy in the denervated hemidiaphragm of the rat. Sci Sin 1965, 14:1772–1784.
28. Gutmann E, Hanikova M, Hajek, I, Klicpera M, Syrovy I: The postdenervation hypertrophy of the diaphragm. Phraim Bohemoslov 1966, 15:508–524.
29. Green JH, Reichmann H, Peretz O: Inter- and intraspecies comparisons of fibre type distribution and of succinate dehydrogenase activity in type I, IIA and IIB fibres of mammalian diaphragms, Histochemistry 1984, 81:57–73.
30. Carlson CJ, Booth FW, Gordon SE: Skeletal muscle myostatin mRNA expression is fiber-type specific and increases during hindlimb unloading. Am J Physiol 1999, 277:E601–E606.
29. Sher J, Cardasis C: Skeletal muscle fiber types in the adult mouse. Acta Neurol Scand 1976, 54:45–56.

30. Berthod M, Coletto L, Sandri M: Posttranslational modifications control FoxO3 activity during denervation. Am J Physiol Cell Physiol 2012, 302: C387–C396.

31. Lokireddy S, Wijesoma IW, Teng S, Bonna S, Gluckman PO, McFarlane C, Sharma M, Kambadur R: The ubiquitin ligase Mul1 induces mitophagy in skeletal muscle in response to muscle-wasting stimuli. Cell Metab 2012, 16:613–624.

32. Wei B, Dui W, Liu D, Xing Y, Yuan Z, Ji G: MST1, a key player, in enhancing fast skeletal muscle atrophy. BMC Biol 2013, 11:12.

33. Kang J, Jeong MJ, Oh S, Jang EI, Kim HK, Hwang EE: A FoxO1-dependent, but NRF2-independent induction of heme oxygenase-1 during muscle atrophy. FEBS Lett 2014, 588:79–85.

34. Huey KA, Bodine SC: Changes in myosin mRNA and protein expression in denervated rat soleus and tibialis anterior. Eur J Biochem/FEBS 1998, 256:45–50.

35. Loughna PT, Morgan MJ: Passive stretch modulates denervation induced alterations in skeletal muscle myosin heavy chain mRNA levels. Plugs Arch 1999, 439:52–55.

36. Goodman CA, Frey JW, Mabrey DM, Jacobs BL, Lincoln HC, You JS, Homburger TA: The role of skeletal muscle mTOR in the regulation of mechanical load-induced growth. J Physiol 2011, 589:5485–5501.

37. Baehr LM, Tunzi M, Bodine SC: Muscle hypertrophy is associated with increases in proteasome activity that is independent of MuRF1 and MAFbx expression. Front Physiol 2014, 5:69.

38. Argadine HM, Mantilla CB, Zhan WZ, Sieck GC: Intracellular signaling pathways regulating net protein balance following diaphragm muscle denervation. Am J Physiol Cell Physiol 2011, 300:C318–C327.

39. Cohen S, Brautl J, GygI SP, Glass DJ, Valenzuela DM, Gartner C, Latres E, Goldberg AL: During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol 2009, 185:1083–1095.

40. Morisot A, Baptista IL, Bogomolovas J, Witt C, Hirner S, Granzier H, Labeit S: MuRF1 is a muscle fiber-type II associated factor and together with MURF2 regulates type II fiber trophicity and maintenance. J Struct Biol 2010, 170:344–353.

41. Argadine HM, Mantilla CB, Zhan WZ, Sieck GC: The effect of denervation on protein synthesis and degradation in adult rat diaphragm muscle. J Appl Physiol 2009, 107:438–444.

42. Morei V, Williams AH, Meadows E, Flynn JM, Pothon MJ, McNally J, Shelton JM, Backs J, Klein WH, Richardson JA, Basel-Duby R, Olson EN: Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell 2010, 143:35–45.

43. Macpherson PC, Wang X, Goldman D: Myogenin regulates denervation-dependent muscle atrophy in mouse soleus muscle. J Cell Biochem 2011, 112:2149–2159.

44. Duckert A, Piette J, Changeux JP: Influence of innervation of myogenic factors and acetylcholine receptor alpha-subunit mRNAs. Neuroreport 1991, 2:5–28.

45. Efstratie R, Brenner HR, Buonnanno A: Myogenin and MyoD join a family of skeletal muscle genes regulated by electrical activity. Proc Natl Acad Sci U S A 1991, 88:1349–1353.

46. Wittemann V, Sakmann B: Differential regulation of MyoD and myogenin mRNA levels by nerve induced muscle activity. FEBS Lett 1991, 282:259–264.

47. Piera S, Mankoo B, Gautel M: Developmental regulation of MURF E3 ubiquitin ligases in skeletal muscle. J Muscle Res Cell Motil 2012, 33:107–122.

48. Ausoni S, Garza L, Schiaffino S, Gundersen K, Lomo T: Expression of myosin heavy chain isoforms in stimulated fast and slow rat muscles. J Neurosci Off J Soc Neurosci 1990, 10:153–160.

49. Schiaffino S, Sandri M, Murgia M: Activity-dependent signaling pathways controlling muscle diversity and plasticity. Physiology (Bethesda) 2007, 22:269–278.

50. Magnusson C, Hagklint L, Libellus R, Tagerud S: Expression of mRNA for plasminogen activators and protease nexin-1 in innervated and denervated mouse skeletal muscle. J Neurosci Res 2001, 66:457–463.

51. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248–254.

52. Siegel AL, Bledsoe C, Lavin J, Gatti F, Benge J, Millman G, Turin E, Winders WT, Rutter J, Palmeiri B, Carlson CG: Treatment with inhibitors of the NF-kappaB pathway improves whole body tension development in the mdx mouse. Neuro muscular Disord: NMD 2009, 19:131–139.

53. Evertsson K, Fjallström AK, Norby M, Tagerud S: p38 mitogen-activated protein kinase and mitogen-activated protein kinase-activated protein kinase 2 (MK2) signaling in atrophic and hypertrophic denervated mouse skeletal muscle. J Mol Signal 2014, 9:2.